MCL1 and acute myeloid leukemia: A study by Niu et al. revealed that incorporating cytarabine or daunorubicin upon VTX treatment resulted in increased DNA damage and a better reduction in MCL-1 levels in AML cell lines than during VTX monotherapy [105].